ANI Pharmaceuticals ANIP Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's stock issuance proceeds?
- ANI Pharmaceuticals (ANIP) reported stock issuance proceeds of $2.2M in Q1 2026.
- How has ANI Pharmaceuticals's stock issuance proceeds changed year-over-year?
- ANI Pharmaceuticals's stock issuance proceeds decreased by 13.1% year-over-year, from $2.53M to $2.2M.
- What is the long-term trend for ANI Pharmaceuticals's stock issuance proceeds?
- Over 3 years (2021 to 2025), ANI Pharmaceuticals's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $69.58M to $0.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.